Publicacións (21) Publicacións de Ana María Carballo Castro

2023

  1. Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types

    JNCI Cancer Spectrum, Vol. 7, Núm. 6

2022

  1. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466

2021

  1. Neoadjuvant, adjuvant, and intraoperative radiotherapy for rectal cancer

    Foundations of Colorectal Cancer (Elsevier), pp. 403-419

  2. Radiotherapy (stereotactic body radiotherapy) for oligometastatic disease

    Foundations of Colorectal Cancer (Elsevier), pp. 421-427

2020

  1. Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy

    Journal of the National Cancer Institute, Vol. 112, Núm. 2, pp. 179-190

2019

  1. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)

    Nature Communications

  2. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

    Radiotherapy and Oncology, Vol. 138, pp. 59-67

2018

  1. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

    Nature Communications, Vol. 9, Núm. 1

  2. Germline variation at 8q24 and prostate cancer risk in men of European ancestry

    Nature Communications, Vol. 9, Núm. 1

2016

  1. Advanced imaging of colorectal cancer: From anatomy to molecular imaging

    Insights into Imaging, Vol. 7, Núm. 3, pp. 285-309

  2. Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer

    EBioMedicine, Vol. 10, pp. 150-163

2014

  1. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1

    Nature Genetics, Vol. 46, Núm. 8, pp. 891-894

2012

  1. Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients

    Radiotherapy and Oncology, Vol. 105, Núm. 3, pp. 321-328

  2. TGFβ1 SNPs and radio-induced toxicity in prostate cancer patients

    Radiotherapy and Oncology, Vol. 103, Núm. 2, pp. 206-209

2011

  1. BRCA1 mutations do not increase prostate cancer risk: Results from a meta-analysis including new data

    Prostate, Vol. 71, Núm. 16, pp. 1768-1779

2010

  1. Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery

    Cancer Chemotherapy and Pharmacology, Vol. 66, Núm. 3, pp. 567-573

  2. Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy

    Clinical and Translational Oncology, Vol. 12, Núm. 12, pp. 843-848

  3. Poxviral-based prostate-specific antigen vaccine in prostate cancer

    Journal of Clinical Oncology

2009

  1. Brain metastases from prostate adenocarcinoma

    Clinical and Translational Oncology, Vol. 11, Núm. 1, pp. 63-64

2003

  1. Síndrome de hipersensibilidad del seno carotídeo asociado a neoplasia cervical

    Revista de oncología: Publicación oficial de la Federación de Sociedades Españolas de Oncología y del Instituto Nacional de Cancerología de México, Vol. 5, Núm. 9, pp. 545-549